Characterization of renal masses with computed tomography (CT) and magnetic resonance (MR) imaging is usually clear-cut and accurate. However, potential pitfalls exist in diagnosis of renal masses, and it is necessary to understand these pitfalls to avoid misdiagnosis and possibly unnecessary surgery. Although some of the pitfalls are related to technical factors of the CT and MR imaging equipment, others are related to errors in image interpretation. To maximize detection and characterization of renal masses, the study should include images obtained before and after administration of intravenous contrast material, including images obtained during the nephrographic phase of enhancement. One should be aware of the potential unreliability of absolute Hounsfield unit measurements and of the existence of possible CT pseudoenhancement. When CT results are indeterminate, MR imaging may be helpful in demonstrating enhancement in renal masses. Before diagnosing a renal mass as a malignant neoplasm or suggesting surgery for a renal mass, one should consider alternative benign diagnoses; when appropriate, previous images or a supporting history should be obtained.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1148/rg.285075744 | DOI Listing |
Minerva Urol Nephrol
December 2024
European Association of Urology (EAU), Young Academic Urologists (YAU) Renal Cancer Working Group, Arnhem, the Netherlands.
Background: Bilateral synchronous renal masses (BSRMs) are a rare finding, and the optimal treatment strategy remains undetermined. This study depicts the management of BSRM at eight European high-volume centers.
Methods: This is a retrospective analysis of prospective institutional databases collecting all patients presenting with clinical T1-2 N0 M0 BSRMs between 1993 and 2020 at 8 tertiary referral high-volume centers for renal cancer treatment in Europe.
Objective: To assess the efficacy of renal score grading in guiding therapy decisions, predicting perioperative outcomes, and characterising tumours following partial nephrectomy.
Methods: The retrospective, single-centre study was conducted at the University College Hospital Galway, Ireland, and comprised data from January 11, 2012, to June 17, 2016, of all patients aged >18 years who underwent partial nephrectomy as part of treatment for kidney cancer. Data was analysed using SPSS 20.
Acad Radiol
January 2025
Department of Diagnostic and Therapeutic Ultrasonography, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China (C.L., X.W., T.Z., X.W.); National Clinical Research Center for Cancer, Tianjin, China (C.L., L.Q., C.G., H.X., X.W., T.Z., Z.Z., X.W.); Key laboratory of Cancer Prevention and Therapy, Tianjin, China (C.L., L.Q., C.G., H.X., X.W., T.Z., Z.Z., X.W.); Tianjin's Clinical Research Center for Cancer, Tianjin, China (C.L., L.Q., C.G., H.X., X.W., T.Z., Z.Z., X.W.). Electronic address:
Rationale And Objectives: Accurate distinguish malignant from benign renal masses remains a challenge for radiologists. The purpose of this study was to evaluate the value of Color Doppler Flow Imaging (CDFI), MicroFlow Imaging (MFI) and Contrast-enhanced Ultrasound (CEUS) in diagnosing solid renal tumors.
Materials And Methods: A total of 291 patients with 300 solid renal tumors pathologically confirmed were retrospectively analyzed between January 2020 and December 2022.
JACC Case Rep
January 2025
Division of Cardiothoracic Surgery, Department of Surgery, Virginia Commonwealth University, Richmond, Virginia, USA.
Extracavitary cardiac calcific amorphous tumors/masses are extremely rare. We present a case report of a 62-year-old man with end-stage renal disease who presented with extracavitary cardiac calcific amorphous tumors/masses compressing the biventricular outflow tracts, resulting in hemodynamic compromise and progressive limitation of activities. The patient was successfully treated with surgery, with complete resolution of symptoms and markedly improved quality of life.
View Article and Find Full Text PDFExpert Rev Anticancer Ther
January 2025
Department of Biomedical Science, Humanitas University, Pieve Emanuele, Milan, Italy.
Small renal masses (SRM), especially those under 7 cm pose significant diagnostic challenges when using conventional imaging (CT/MRI). PET/CT with [Zr]Zr-girentuximab offers a promising alternative in this setting by enabling molecular-level imaging. The ZIRCON trial, a phase 3 multicenter study, evaluated the diagnostic accuracy of [Zr]Zr-girentuximab PET/CT in detecting clear cell renal cell carcinoma (ccRCC) in SRM.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!